JP2022501327A5 - - Google Patents

Info

Publication number
JP2022501327A5
JP2022501327A5 JP2021512742A JP2021512742A JP2022501327A5 JP 2022501327 A5 JP2022501327 A5 JP 2022501327A5 JP 2021512742 A JP2021512742 A JP 2021512742A JP 2021512742 A JP2021512742 A JP 2021512742A JP 2022501327 A5 JP2022501327 A5 JP 2022501327A5
Authority
JP
Japan
Prior art keywords
compound
compound according
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021512742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501327A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049784 external-priority patent/WO2020051356A1/en
Publication of JP2022501327A publication Critical patent/JP2022501327A/ja
Publication of JP2022501327A5 publication Critical patent/JP2022501327A5/ja
Pending legal-status Critical Current

Links

JP2021512742A 2018-09-07 2019-09-05 イミダゾキノリン化合物およびその使用 Pending JP2022501327A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728556P 2018-09-07 2018-09-07
US62/728,556 2018-09-07
PCT/US2019/049784 WO2020051356A1 (en) 2018-09-07 2019-09-05 Imidazoquinoline compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2022501327A JP2022501327A (ja) 2022-01-06
JP2022501327A5 true JP2022501327A5 (cg-RX-API-DMAC7.html) 2022-07-04

Family

ID=69722888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512742A Pending JP2022501327A (ja) 2018-09-07 2019-09-05 イミダゾキノリン化合物およびその使用

Country Status (9)

Country Link
US (1) US20210214354A1 (cg-RX-API-DMAC7.html)
EP (2) EP4306523A3 (cg-RX-API-DMAC7.html)
JP (1) JP2022501327A (cg-RX-API-DMAC7.html)
KR (1) KR20210074290A (cg-RX-API-DMAC7.html)
CN (1) CN113164460A (cg-RX-API-DMAC7.html)
AU (1) AU2019335366A1 (cg-RX-API-DMAC7.html)
CA (1) CA3111786A1 (cg-RX-API-DMAC7.html)
ES (1) ES2963112T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020051356A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
DK4001311T3 (da) 2014-07-09 2026-02-02 Birdie Biopharmaceuticals Inc Anti-pd-l1/pd-1-kombinationer til behandling af tumorer
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-egfr组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-her2组合
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
FI3641771T3 (fi) 2017-06-23 2026-08-11 Birdie Biopharmaceuticals Inc Farmaseuttisia koostumuksia
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
BR112022008039A2 (pt) * 2019-10-29 2022-07-12 Prime Reach Trading Ltd Compostos de 4-amino-imidazoquinolina e usos relacionados
AU2021305193A1 (en) * 2020-07-08 2023-02-09 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US689338A (en) * 1901-03-29 1901-12-17 Nat Faucet Company Tapping-bung.
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP1667694B1 (en) * 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
AU2005284835A1 (en) * 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US9034336B2 (en) * 2011-08-30 2015-05-19 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
ES2804101T3 (es) * 2014-04-22 2021-02-03 Hoffmann La Roche Compuestos de 4-amino-imidazoquinolina
DK4001311T3 (da) * 2014-07-09 2026-02-02 Birdie Biopharmaceuticals Inc Anti-pd-l1/pd-1-kombinationer til behandling af tumorer
CN112546230A (zh) * 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
CN106943598A (zh) * 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-her2组合

Similar Documents

Publication Publication Date Title
JP2021522249A5 (cg-RX-API-DMAC7.html)
JP2022031403A5 (cg-RX-API-DMAC7.html)
JP2020037585A5 (cg-RX-API-DMAC7.html)
JP2020125349A5 (cg-RX-API-DMAC7.html)
JP2020532547A5 (cg-RX-API-DMAC7.html)
JP2012529486A5 (cg-RX-API-DMAC7.html)
JP2018070614A5 (cg-RX-API-DMAC7.html)
JP2015536986A5 (cg-RX-API-DMAC7.html)
JP2024547131A5 (cg-RX-API-DMAC7.html)
JP2017530118A5 (cg-RX-API-DMAC7.html)
JP2021534158A5 (cg-RX-API-DMAC7.html)
JP2009538327A5 (cg-RX-API-DMAC7.html)
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2005508337A5 (cg-RX-API-DMAC7.html)
JP2022511477A5 (cg-RX-API-DMAC7.html)
JP2025502064A5 (cg-RX-API-DMAC7.html)
JP2015517523A5 (cg-RX-API-DMAC7.html)
RU2014141934A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями
JP2019529460A5 (cg-RX-API-DMAC7.html)
RU2005138124A (ru) Производные тетрагидрокарбазола и их фармацевтическое применение
JP2007501284A5 (cg-RX-API-DMAC7.html)
JP2022169780A5 (cg-RX-API-DMAC7.html)
Yang et al. Advances in development of antiviral strategies against respiratory syncytial virus
JP2022551691A5 (cg-RX-API-DMAC7.html)
RU2017124371A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина